Axumin (fluciclovine F 18) injection has been added to the National Comprehensive Cancer Network® (“NCCN”) Clinical Practice Guidelines in Oncology for Prostate Cancer.
This coming Wednesday, February 21, at 5:00 p.m. Eastern time (2:00 p.m. Pacific), Cancer ABCs will be collaborating with Cure Talks, The topic of the conversation will be It the recently launched “Metastatic Prostate Cancer Project”.
he FDA approved a new advanced hormone therapy drug (a next-generation androgen receptor inhibitor) for the treatment of men with non-metastatic castration-resistant prostate cancer (NM-CRPC). This drug with the trade name Erleada (aka apalutamide), is the first drug approved in this disease space.
The Food and Drug Administration approved the use of abiraterone acetate (Zytiga) with prednisone for men with high-risk, castration-sensitive, chemotherapy-naive metastatic prostate cancer, but there are some hitches and hurdles.
Two different trials, SPARTAN and PROSPER, are reporting top-line results in the treatment of men with nmCRPC. The full results of these trials will be presented today at the Genitourinary Cancer Symposium in San Francisco where Cancer ABCs is in attendance.
Early results from an international, open-label, phase 1/2 trial (NCT01934790) showed that it is possible to successfully re-treat men with the drug known as Xofigo (Ra-223). The study found that when used a second time, Xofigo was well tolerated and that it provides favorable effects on the cancer’s progression.
Like all of the other advanced prostate cancer treatments currently available, enzalutamide (Xtandi) lasts for a limited time. When Xtandi stops working we refer to this as developing resistance.
You have become castrate resistant and already have taken Provenge. Now, what treatment should be next? Currently, the two best options are either Zytiga (abiraterone) or Xtandi (enzalutamide). Which should come first?
There is often a choice is between using the LHRH agonist drug (Lupron, Trelstar) or using the gonadotrophin-releasing hormone (GnRH) antagonist like Firmagon.
This brings us to the question, which of these two drugs is superior?
The European Union has recently placed some restrictions on the use of the MRI contrast agent Gadolinium. There has been concern expressed by recent findings that Gadolinium doesn’t wholly disappear or wash out of a person’s body, but instead stays in a person’s brain.
Docetaxel combined with ADT, in men with hormone sensitive prostate cancer, when prescribed as per a study’s protocol led to significantly longer overall survival as well as other positive effects in men with metastatic hormone-sensitive prostate cancer who received only ADT.
Today is an important day, we launched the Metastatic Prostate Cancer Project (https://mpcproject.org/home ). The project will help understand an individual's genetics and their tumor genetics in relation to treatment responses. The project's findings will be fed back to the study's participants (which could be you) as well as prostate cancer researchers worldwide.
Bipolar Androgen Therapy (BAT) can be used to treat metastatic castrate resistant prostate cancer (mCRPC) and to reverse Xtandi treatment resistance.
The American Society of Clinical Oncology (ACSO), warns that people drinking alcoholic drinks face a significantly increased risk of developing cancer(s).
Earlier studies of men with metastatic prostate cancer who took enzalutamide (Xtandi) indicated that there might be an increase in the risk having a seizure. Is this risk real? The UPWARD Study
The opinion of two Professionals in the know, - Gleason 9 and Gleason 10 prostate cancer is best treated by multiple modalities; surgery, radiation and hormone therapy used in combination.
Liquid biopsies remain a promising technology, but they are still far from being ready for prime time. They are not yet ready for clinical use.
Zytiga has now been approved for earlier use in the European Union. Now men who are newly diagnosed with metastatic prostate cancer can receive Zytiga along with prednisone and ADT.
Despite the fact that the prognosis of prostate cancer is mainly determined by the presence or absence of metastases little is known about the actual metastatic pathways in prostate cancer. Research has described the metastatic pathways taken by prostate cancer.
Foundation One has announced that The Food and Drug Administration (FDA) has approved a “breakthrough device” that has the potential to match cancer patients with more accurate individualized treatment regiments with just one test. This test will push the boundaries of personalized medicine as it might allow us to choose better treatments that are most likely to be effective for specific types of cancer — and to make those decisions sooner.